rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SXTP
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      60 Degrees Pharmaceuticals Announces Warrant Inducement Financing Agreement

      Tipranks Press Release.

      Nov 7The Globe and MailSXTP
      Join 60 Degrees Pharmaceuticals' Live Investor Webinar: Advancing Tafenoquine for Babesiosis While Expanding ARAKODA(R) Commercialization
      Nov 4Yahoo FinanceSXTP
      60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome

      Company plans to explore botanical approval pathways before initiating a prescription drug development programWASHINGTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, today announced expansion of its vector-borne disease research portfolio through a sponsored research agreement with The University of Southern Mississippi (USM) to assess the therapeu

      Oct 28Yahoo FinanceSXTP
      60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients
      Oct 27Yahoo FinanceSXTP
      60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting

      60 Degrees Pharmaceuticals plans to report results from its hospitalized severe babesiosis study in January 2027 and seek FDA feedback that month on a potential supplemental New Drug Application pathway for tafenoquine. Key Investor Takeaways60 Degrees Pharmaceuticals (NASDAQ:SXTP) plans a January 2027 babesiosis data readout from its randomized study of tafenoquine in hospitalized patients.

      Oct 6Yahoo FinanceSXTP
      60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
      Oct 6Yahoo FinanceSXTP
      60 Degrees Pharmaceuticals Shares Rise 12.5% Premarket - 60 Degrees (NASDAQ:SXTP)

      60 Degrees Pharmaceuticals shares rose 12.50% in premarket trading Tuesday ahead of interim data from its babesiosis treatment study.

      Oct 6BenzingaSXTP
      60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

      ORLANDO, FL / ACCESS Newswire / October 2, 2026 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP; SXTPW) and Exyn Technologies Inc.

      Oct 2Yahoo FinanceSXTP
      60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

      Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier. WASHINGTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector

      Oct 1Yahoo FinanceSXTP
      60 Degrees Pharmaceuticals at H.C. Wainwright: babesiosis push in focus
      Sep 11Investing.comSXTP
      60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference

      – On-demand company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET – – Management will be available for one-on-one investor meetings during the conference – WASHINGTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, today announced that management will participate in the H.C. Wainwright 28th Annual

      Sep 3Yahoo FinanceSXTP

      This is the newest page. Registered accounts read further back.